Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 19/20 | 0.83 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16774261 | 1.00 | ADORA3 (0.83) | ADORA3TMIGD3ADORA2AADORA1HTR2B | |
| SCHEMBL18352572 | 0.93 | ADORA3 (0.71) | ADORA3TMIGD3ADORA2AADORA1HTR2B | |
| SCHEMBL16774187 | 0.91 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL20122172 | 0.91 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL30255348 | 0.91 | ADORA3 (1.00) | ADORA3 | |
| SCHEMBL20122119 | 0.86 | ADORA3 (0.61) | ADORA3TMIGD3ADORA2AADORA1HTR2B | |
| SCHEMBL18352607 | 0.84 | ADORA3 (0.86) | ADORA3ADORA2A | |
| SCHEMBL16774291 | 0.83 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1 | |
| SCHEMBL16774154 | 0.83 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1 | |
| SCHEMBL20122127 | 0.83 | ADORA3 (1.00) | ADORA3TMIGD3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074398-B1 | A3 ADENOSINE RECEPTOR AGONISTS | US HEALTH (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020168274-A1 | TREATMENT OF CHRONIC HEADACHES | SAINT LOUIS UNIVERSITY (US) | 2020-08-20 | — | — | WO | disclosed |
| US-10577368-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-03 | — | — | US | disclosed |
| US-9963450-B2 | A3 adenosine receptor agonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577368-B2 | A3 adenosine receptor agonists | ADORA3, ADORA2B, ADORA1 | ADORA3 1/4885TMIGD3 3740/4885ADORA2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.